Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma

[Aim]: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies we...

Descripción completa

Detalles Bibliográficos
Autores: Hajek, Roman, Minařík, Jiří, Straub, Jan, Pour, Ludek, Jungova, Alexandra, Berdeja, Jesús G., Boccadoro, Mario, Brozova, Lucie, Spencer, Andrew, Rhee, Frits van, Vela-Ojeda, Jorge, Thompson, Michael A., Abonour, Rafat, Chari, Ajai, Cook, Gordon, Costello, Caitlin L., Davies, Faith E., Hungria, Vania, Lee, Hans C., Leleu, Xavier, Puig, Noemi, Rifkin, Robert M., Terpos, Evangelos, Usmani, Saad Z., Weisel, Katja C., Zonder, Jeffrey A., Bařinová, Magda, Kuhn, Matyáš, Šilar, Jiří, Čápková, Lenka, Galvez, Kenny, Lu, Jin, Elliott, Jennifer, Stull, Dawn Marie, Ren, Kaili, Maisnar, Vladimir
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/261619
Acceso en línea:http://hdl.handle.net/10261/261619
Access Level:acceso abierto
Palabra clave:Effectiveness
Ixazomib
Multiple myeloma
Proteasome inhibitors
Relapsed/refractory
Routine clinical practice
Descripción
Sumario:[Aim]: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed.

Similares en LA Referencia